UTHealth
Houston, Texas, 77030, United States
NCT Number: NCT03514784
This protocol is a blinded randomized controlled study of the effects of BB-12 with LGG at different doses in 70 healthy children with autism spectrum disorders at lower and higher doses over an 56-day period and a 28- day observation period. The study is being conducted in order to assess safety and tolerability of the probiotic (BB-12 with LGG) at 2 different doses of BB-12 with LGG. Identifying effects on behaviors in healthy children with ASD using SRS-2 and ABC, GI symptoms using GI symptom severity index, and relevant biomarkers of inflammation, microbiota, and metabolites. Primary testing and procedures will be conducted at the University of Texas Health Science Center at Houston and Memorial Hermann.
Biomarker identification includes Integrative analysis of plasma metabolome and stool microbiota will be conducted with the collaboration of Dr. Ruth Ann Luna and Dr. Jim Versalovic at Alkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology & Microbiology of Baylor College of Medicine.
Looking for future studies?
Notify Me4 year–16 year
All sexes
Interventional
Phase 1 / Phase 2
Houston, Texas, 77030, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
BB-12 with LGG - Higher Dose (10 billion CFUs)
Other names: Probiotic
Maltodextrin
Other names: Maltodextrin
BB-12 with LGG - Lower Dose (1 billion CFUs)
Other names: Probiotic
Time frame: 84 days
Adverse events (Safety) will be measured by case report form (survey) that are related to BB-12 with LGG (health-promoting bacteria) or placebo treatment. The symptom grade will detail the severity of adverse events.
Time frame: Days 1, 21, 56 and 84
Psychological/Behavioral change in irritability and related maladaptive behaviors associated with ASD will be measured by the Aberrant Behavior Checklist (ABC)-2 pre and post treatment
Time frame: Days 1, 21, 56 and 84
Psychological/Behavioral change in irritability and related maladaptive behaviors associated with ASD will be measured by the and the Social Responsiveness Scale-2 (SRS-2) pre and post treatment.
Time frame: Days 1, 21, 56 and 84
GI symptoms will be measured by the GI Severity Index.
Time frame: Days 1, 56 and 84
Plasma S100A9 will indicate GI and systemic levels of inflammation. S100A9 is a damage-associated molecular pattern molecule (DAMP) released by granulocytes, which is reportedly elevated 2-fold in plasma of children with ASD.
Time frame: Days 1, 56 and 84
Biological change in fecal calprotectin levels. FC is a highly accurate fecal marker of inflammation.
Time frame: Days 1, 56 and 84
Plasma zonulin, a marker for intestinal permeability ("leaky gut"), which is often associated with inflammation.
Time frame: Days 1, 56 and 84
IL-8 can be an indicator of gut inflammation; it released from the intestinal epithelial cells during inflammation.
Time frame: Days 1, 56 and 84
Using 16S rDNA analysis, this will determine microbial alpha and beta diversity and distribution of the major taxa before and after probiotic treatment.
Time frame: Days 1, 56 and 84
This will determine levels of metabolic markers which are reported to be abnormal in autism: fecal amino acids, ammonia, short chain fatty acids (SCFA), and phenols.
The University of Texas Health Science Center, Houston
Other
Road to Discovery for Combination Probiotic BB-12 With LGG (Different Doses) in Treating Autism Spectrum Disorder Disorders
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03369431
Autism Spectrum Disorder, Autistic Disorder
London, United Kingdom
View Trial DetailsNCT04182633
Autism Spectrum Disorder, Autistic Disorder
Tempe, Arizona, United States
View Trial DetailsNCT06503978
Autism Spectrum Disorder, Child Development Disorders, Pervasive
Tempe, Arizona, United States
View Trial DetailsNCT03197922
Autism Spectrum Disorder, Behavior
Atlanta, Georgia, United States
View Trial Details